文献速递泌尿男性生殖肿瘤

前列腺癌管腔型与基底型亚型分类与预后及雄激素剥夺治疗反应的相关性

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
PubMed 文献 · JAMA Oncol · 2017-01-01

研究使用PAM50分类器将3782例前列腺癌样本分为管腔A型、管腔B型和基底型,发现管腔B型预后最差,且管腔B型肿瘤患者术后接受雄激素剥夺治疗(ADT)的转移风险低于未治疗者,而非管腔B型患者接受ADT后转移风险反而高于未治疗者。

要点

  • PAM50分类器可将前列腺癌分为管腔A型、管腔B型和基底型三种亚型。
  • 回顾性队列中管腔B型前列腺癌的10年预后最差。
  • 管腔B型患者术后ADT与较低转移风险相关,非管腔B型患者则相反。

核心结论

  • 管腔型和基底型前列腺癌表现出不同的临床行为,管腔B型肿瘤患者术后对ADT的反应优于非管腔B型肿瘤患者。

研究设计与样本

  • 使用PAM50分类器对1567例回顾性收集(中位随访10年)和2215例前瞻性收集的前列腺癌样本进行管腔型和基底型亚型分类。

主要发现

  • 在3782例样本中,PAM50分类器在回顾性和前瞻性队列中均一致地将前列腺癌分为3种亚型:管腔A型(回顾性538例[34.3%];前瞻性737例[33.3%])、管腔B型(回顾性447例[28.5%];前瞻性723例[32.6%])和基底型(回顾性582例[37.1%];前瞻性755例[34.1%])。
  • 在回顾性队列中,管腔B型前列腺癌在单变量和多变量分析中均表现出最差的临床预后(10年生化复发无生存率[bRFS]29%;无远处转移生存率[DMFS]53%;前列腺癌特异性生存率[PCSS]78%;总生存率[OS]69%),其次为基底型(10年bRFS 39%;DMFS 73%;PCSS 86%;OS 80%)和管腔A型(10年bRFS 41%;DMFS 73%;PCSS 89%;OS 82%)。
  • 在回顾性队列中按临床病理变量匹配的子集分析(n=315)中,管腔B型前列腺癌术后ADT治疗与未治疗的10年转移率分别为33%和55%;非管腔B型前列腺癌术后ADT治疗与未治疗的10年转移率分别为37%和21%;交互作用P=0.006。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is a clear need for a molecular subtyping approach in prostate cancer to identify clinically distinct subgroups that benefit from specific therapies. OBJECTIVES: To identify prostate cancer subtypes based on luminal and basal lineage and to determine associations with clinical outcomes and response to treatment. DESIGN, SETTING, AND PARTICIPANTS: The PAM50 classifier was used to subtype 1567 retrospectively collected (median follow-up, 10 years) and 2215 prospectively collected prostate cancer samples into luminal- and basal-like subtypes. MAIN OUTCOMES AND MEASURES: Metastasis, biochemical recurrence, overall survival, prostate cancer–specific survival, associations with biological pathways, and clinicopathologic variables were the main outcomes. RESULTS: Among the 3782 samples, the PAM50 classifier consistently segregated prostate cancer into 3 subtypes in both the retrospective and prospective cohorts: luminal A (retrospective, 538 [34.3%]; prospective, 737 [33.3%]), luminal B (retrospective, 447 [28.5%]; prospective, 723 [32.6%]), and basal (retrospective, 582 [37.1%]; prospective, 755 [34.1%]). Known luminal lineage markers, such as NKX3.1 and KRT18, were enriched in luminal-like cancers, and the basal lineage CD49f signature was enriched in basal-like cancers, demonstrating the connection between these subtypes and established prostate cancer biology. In the retrospective cohort, luminal B prostate cancers exhibited the poorest clinical prognoses on both univariable and multivariable analyses accounting for standard clinicopathologic prognostic factors (10-year biochemical recurrence-free survival [bRFS], 29%; distant metastasis-free survival [DMFS], 53%; prostate cancer-specific survival [PCSS], 78%; overall survival [OS], 69%), followed by basal prostate cancers (10-year bRFS, 39%; DMFS, 73%; PCSS, 86%; OS, 80%) and luminal A prostate cancers (10-year bRFS, 41%; DMFS, 73%; PCSS, 89%; OS, 82%). Although both luminal-like subtypes were associated with increased androgen receptor expression and signaling, only luminal B prostate cancers were significantly associated with postoperative response to androgen deprivation therapy (ADT) in a subset analysis in our retrospective cohorts (n = 315) matching patients based on clinicopathologic variables (luminal B 10-year metastasis: treated, 33% vs untreated, 55%; nonluminal B 10-year metastasis: treated, 37% vs untreated, 21%; P = .006 for interaction). CONCLUSIONS AND RELEVANCE: Luminal- and basal-like prostate cancers demonstrate divergent clinical behavior, and patients with luminal B tumors respond better to postoperative ADT than do patients with non–luminal B tumors. These findings contribute novel insight into prostate cancer biology, providing a potential clinical tool to personalize ADT treatment for prostate cancer by predicting which men may benefit from ADT after surgery.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao SG, Chang SL, Erho N, et al. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017. PMID: 28494073. doi:10.1001/jamaoncol.2017.0751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。